Moving on to the common cold, caused by the rhinovirus, the UKHSA explains that symptoms develop gradually over a few days.

More than 86,000 recorded cases of respiratory syncytial virus in 2024 were in children younger than four years old.

Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.

COVID-19 was associated with more severe disease outcomes than influenza or respiratory syncytial virus (RSV) during ...

Learn about respiratory viruses during viral season and how to stay safe. Dr. Matthew Muller discusses COVID-19, RSV, influenza, and more.

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...

Lower rates of both progression of macular fibrosis and intravitreal aflibercept injections were found in those who used the ...

Anne Murray sang Everything Old Is New Again on episode 415 of The Muppet Show, which aired on February 1, 1980 in the United ...

While RSV isn’t any more virulent than the cold, flu or COVID, the same precautions are recommended in order to control its ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...